CRISPR/Cas-based CAR-T cells: production and application.

Area of Science:

• Biotechnology
• Immunotherapy
• Gene Editing

Background:

• Chimeric antigen receptor T cell (CAR-T) therapy shows promise for treating cancer, autoimmune, and heart diseases.
• Current CAR-T cell development relies on viral vectors for CAR gene integration, which can cause adverse effects like oncogenic transformation and variegated transgene expression.
• Random CAR gene insertion poses challenges for CAR-T cell therapy's clinical translation and efficacy.

Purpose of the Study:

• To review the application of CRISPR gene editing techniques for precise CAR gene insertion and deletion in T cells.
• To analyze the potential of CRISPR-mediated gene editing to enhance CAR-T cell therapy development and clinical utility.
• To highlight CRISPR's role in overcoming the limitations associated with traditional viral vector-based CAR-T cell generation.

Main Methods:

• Review of scientific literature on CRISPR gene editing applications in CAR-T cell therapy.
• Analysis of precise deletion and insertion methodologies facilitated by CRISPR technology.
• Evaluation of CRISPR's impact on CAR-T cell function, safety, and therapeutic potential.

Main Results:

• CRISPR enables precise, targeted integration of CAR genes into specific genomic loci within T cells.
• CRISPR technology mitigates risks associated with random viral vector insertion, such as oncogenesis and gene silencing.
• CRISPR facilitates the development of safer and more effective CAR-T cell therapies with predictable transgene expression.

Conclusions:

• CRISPR gene editing represents a significant advancement for CAR-T cell therapy, enabling precise genomic modifications.
• The application of CRISPR technology enhances the safety and efficacy of CAR-T cell therapies by ensuring controlled gene integration.
• CRISPR-mediated strategies are crucial for accelerating the clinical translation and expanding the therapeutic applications of CAR-T cell therapy.